Novartis & BMS CAR-T Cell Trials on Hold
Reuters and the Wall Street Journal report that both Novartis and Bristol Myers Squibb (BMS) have paused their autoimmune disease CAR-T ce
Read ArticleMost Popular
Insights into Sjögren’s Disease - A Rheum Survey
Key Rheumatologist Takeaways on Sjogren’s Disease:
Read Article
A Tribute to Thomas A. Medsger Jr., MD (1936–2026)
The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89.
Read Article
FDA Approves Brepocitinib to Treat Dermatomyositis
The FDA and Priovant recently annouced approval of brepocitinib (Lisraya), a JAK1/TYK2 inhibitor, for the indication of adults with dermatomyositis (DM). This is the first oral (once daily) agent approved for DM.
Read Article
Rheum Scholarship (8.21.2026)
Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis. Take the RheumIQ quiz to test your knowledge of this week's news!
Read Article
ACR Updates Osteoarthritis Guidance
ACR
New evidence-based recommendations emphasize exercise, self-management, appropriate weight loss, and shared decision-making; introduce conditional recommendations for GLP-1 receptor agonists in knee osteoarthritis and methotrexate in erosive hand osteoarthritis
Secukinumab in Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a common disorder of the elderly that responds well to glucocorticoids (GC), but is plagued by an inability to wean off of GCs.
Treating Obesity is Disease-Modifying (9.4.2026)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. New drugs approved, new drugs halted and some drugs out of control. Ready to test your knowlege? Take this week's quiz!
Read Article
A Day of Infamy (9.11.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz!
Read Article
NME: New Molecular Entities (8.28.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!
Read Article
Early RA Referral Clinics Work!
An outcomes study from the Leiden Early Arthritis Clinic (EAC) has shown substantially less diagnostic delay and better long-term outcomes when patients are referred to EAC compared to usual referrals.
Registry Data Shows Liver Risk With Avacopan
MedPage Today
Key Takeaways
- The C5a complement inhibitor avacopan (Tavneos) was FDA-approved in 2021 to treat ANCA-associated vasculitis, but questions have been raised about data integrity in the trials supporting that approval.
- As well, an FDA
Osteoarthritis, Obesity and GLP-1s
We all know that osteoarthritis is the most common form of arthritis in the world, and that obesity is its most modifiable risk factor. What I really want to focus on is the role that GLP-! receptor agonists might be playing in our management of osteoarthritis. So why does this matter?
Read Article
EBR Journal Club: Dapirolizumab Pegol in SLE (PHOENYCS GO)
The EBR Journal Club Companion applies my adapted version of the JAMA approach to critical appraisal to an important RCT in rheumatology. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How great are the benefits and harms? And what didn’t they show me?
Read Article
